THE EFFICACY OF PHARMACOTHERAPY IN PATIENTS WITH OSTEOARTHROSIS OF THE KNEE JOINTS WITH ABERRANT 6-SULFATEXYMELATONIN EXCRETION PROFILE
Summary. Summary. We studied the efficacy of pharmacotherapy in patients with osteoarthrosis (OA) of knee joints with aberrant production of melatonin. The OA patients with normal excretion of 6-sulfatexymelatonin (6-SMT) treated with a standard pharmacotherapy (diclofenac sodium, glucosamine hydrochloride, chondroitin sulfate) presented with a better pattern of clinical parameters (Lequesne, HAQ, WOMAC, KOOS indices) than did OA subjects with aberrant 6-SMT excretion profile. At Week 12 of treatment, the OA patients with low-excretion of 6-SMT had a proportion of WOMAC20 non-responders 1.7 times higher than those among subjects with normal 6-SMT excretion. The inclusion of melatonin (3 mg/day) in the treatment regimen of OA patients with aberrant 6-SMT excretion profile improved the sleep quality, reduced depression, increased the course of clinical indices (Lequesne, HAQ, WOMAC, KOOS) and tripled the chances of gaining WOMAC20.
No Comments » Add your